Also trades as: 0K16.L (LSE) · $vol 0M
EOLS NASDAQ
Evolus, Inc.
1W: +0.0%
1M: -7.4%
3M: +22.2%
YTD: +9.7%
1Y: +8.5%
3Y: -5.6%
5Y: -7.4%
$7.37
+0.20 (+2.79%)
Weekly Expected Move ±7.9%
$6
$6
$7
$8
$8
Credit Risk of going bust: higher than 71% of companies Debt: 25.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.28 (down 96%), Evolus, Inc. would be worth roughly what it owes.
Total debt $164.8M against a stock market value of $486.8M.
Distance to default 3.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $78.4M (short-term plus half of long-term), stock volatility 64.7%; Altman Z -1.41. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.28 (down 96%), Evolus, Inc. would be worth roughly what it owes.
Total debt $164.8M against a stock market value of $486.8M.
Distance to default 3.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $78.4M (short-term plus half of long-term), stock volatility 64.7%; Altman Z -1.41. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$486.8M
52W Range3.86-9.31
Volume600,999
Avg Volume855,365
Beta1.34
Dividend—
Analyst Ratings
Company Info
CEODavid Moatazedi
Employees353
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2018-02-08
Websiteevolus.com
520 Newport Center Drive
Newport Beach, CA 92660
US
Newport Beach, CA 92660
US
949 284 4555
About Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Latest News
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Evolus drops as FDA says Jeuveau Instagram post is misleading
Corient Private Wealth LP Purchases New Shares in Evolus, Inc. $EOLS
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
625,000 Shares in Evolus, Inc. $EOLS Purchased by AWH Capital L.P.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| MOATAZEDI DAVID | S-Sale | 105,108 | $9.04 | 2026-09-02 |
| Avelar Rui | S-Sale | 3,119 | $4.75 | 2026-03-20 |
| MOATAZEDI DAVID | S-Sale | 13,669 | $4.75 | 2026-03-20 |
| MOATAZEDI DAVID | S-Sale | 116,720 | $4.89 | 2026-03-17 |
| Avelar Rui | S-Sale | 29,996 | $4.89 | 2026-03-17 |